Ed Forum - Day 2
Many people with WM have other relatives with WM, MGUS, or related blood cancers. The question of whether WM is "inherited" is a complicated one. Dr. Mary Lou McMaster (from the National Institutes of Health) will share her many years of research on the nature of familial factors in WM. She will clarify what is meant by "familial" as opposed to "genetic predisposition." She will also discuss the role that environmental factors can play.
A Review of NCCN Guidelines for WM
The National Comprehensive Cancer Network (NCCN) is a not-for -profit alliance of 31 leading cancer center devoted to patient care, research, and education. The NCCN Clinical Practice Guidelines are a statement of evidence and consensus of the experts in WM regarding their views of currently accepted approaches to diagnosis and treatment. The NCCN panel of experts has categorized WM therapy regimens as “preferred regimens,” “other recommended regimens,” and regimens “useful under certain circumstances.' The purpose of classifying regimens is to provide health care providers with guidance on treatment selection considering the relative efficacy, toxicity, and other factors that play into treatment selection such as pre-existing conditions (e.g. peripheral neuropathy, rituximab intolerance). The newest (2021) change to the Guidelines was the addition of zanubrutinib to the list of preferred regimens.